Equities researchers at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) in a research note issued to investors on Saturday. The firm set a "sell" rating on the biotechnology company's stock.
Cyclacel Pharmaceuticals Trading Up 2.6%
Shares of NASDAQ:CYCC traded up $0.06 on Friday, reaching $2.38. 85,347 shares of the company's stock were exchanged, compared to its average volume of 103,167. The company has a fifty day moving average of $4.18 and a 200-day moving average of $5.46. Cyclacel Pharmaceuticals has a twelve month low of $2.21 and a twelve month high of $49.34. The company has a market capitalization of $493.46 million, a price-to-earnings ratio of -0.26 and a beta of 0.52.
Cyclacel Pharmaceuticals (NASDAQ:CYCC - Get Free Report) last posted its quarterly earnings results on Wednesday, April 2nd. The biotechnology company reported ($5.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.64) by ($0.64). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%.
Insider Activity
In other news, CEO David E. Lazar sold 12,164,301 shares of the firm's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $0.48, for a total transaction of $5,838,864.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 68.00% of the company's stock.
Cyclacel Pharmaceuticals Company Profile
(
Get Free Report)
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Articles
Before you consider Cyclacel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cyclacel Pharmaceuticals wasn't on the list.
While Cyclacel Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
